NextPharma Board appoints Sean Marett as Senior Vice President of Business Development
London 31st January, 2006
NextPharma the leading European provider of product development, manufacturing and logistics outsourcing services to the pharmaceutical and biotech industry is pleased to announce the following appointment to its senior management team:
Sean Marett has joined NextPharma as SVP Business Development. Sean has significant experience in business development gained most recently at Lorantis Ltd. where he was responsible for acquiring strategic products. Prior to Lorantis, Sean worked at Evotec where he negotiated three of the largest deals in the history of the company and GSK in new product planning where he was based in the US. Sean holds an MBA from Manchester Business School and a BSc in Biochemistry from Kings College, London.
Bill Wedlake, CEO, NextPharma Technologies, commented as follows:
‘I believe that it is essential that NextPharma continues its track record in acquiring technology and capabilities to match the growing and developing requirements of the pharmaceutical outsourcing industry. Sean’s experience across our industry will significantly enhance our ability to match the demands of our customers providing innovative technical solutions to both our pharmaceutical and biotech customers. It is our objective to ensure that
NextPharma remains at the forefront of timely, competitive, healthcare outsourcing solutions of the highest quality as the pharma and biotech markets continue to develop’
About NextPharma
NextPharma Technologies is a leading independent supplier in the fast growing pharmaceutical and biotech product development, clinical trials supplies, manufacturing and logistics outsourcing sector. It has eight manufacturing and five logistics facilities based in Austria, Belgium, France, Germany and Switzerland employing over 1,200 people and has a customer base which includes many of the world’s leading pharmaceutical, specialty pharma and biotech companies. NextPharma’s principle shareholder is Credit Suisse First Boston Private Equity.
NextPharma Board member Prof Trevor Jones CBE elected to the French Academie nationale de Pharmacie
London 13 January, 2006
NextPharma is delighted to announce that Prof. Trevor Jones CBE who has been on the Board of NextPharma since December 2004 has been elected to the French Academie nationale de Pharmacie at a ceremony held in the ancient Salle des Actes at the University of Paris on 4th January, 2006. Also elected at the same ceremony was Jean-François Dehecq – Chairman and CEO of sanofi aventis.
In his oration, the outgoing President of the Academie, Prof Jean-Pierre Lousson, cited the contribution that Prof. Trevor Jones had made to international pharmaceutical science during his career and his long association with scientists in France. During his time at the Boots Company he was responsible for the technical transfer of Brufen formulations to Labs Dacour in Paris including the development of a suppository formulation. As R&D Director at Wellcome plc he had responsibility for the R&D activities of Wellcome France in Sophie Antipolis and in Paris. During that time his team at Wellcome co-developed the anticancer drug Navelbine with Pierre Fabre. For 13 years he was President of the international jury of the Maurice-Marie Janot Lecture and recently he has become a senior R&D advisor to Labs Servier.
Prior to joining NextPharma Prof Trevor Jones was Director General of the ABPI, he is also a member of the Board of Allergan Inc. and Chairman of the Merlin Bioscience stem cell company ReNeuron.
Bill Wedlake, CEO, NextPharma Technologies, commented on this prestigious appointment as follows:
“Prof Trevor Jones is a highly valued member of the NextPharma Board, since his appointment his knowledge and expertise has been of tremendous benefit to the development of our company. Trevor is widely respected in the industry for his dedication to scientific advancement within the field of pharmaceutical development.”
About NextPharma
NextPharma Technologies is a leading independent supplier in the fast growing biologics and pharma product development, clinical trials packaging, and manufacturing outsourcing sector. It has eight manufacturing facilities based in Germany, Belgium and France employing some 1,200 people and has a customer base which includes many of the worlds leading pharmaceutical companies.
Contact:
Franck Latrille
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel.: +44 (0) 1483 479 120
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is world class provider of product development, contract manufacturing and distribution outsourcing services to the pharmaceutical, specialty pharmaceutical, generics and biotech industry.
It offers a broad range of services from early phase product development, through clinical trials supplies to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill-finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled substances. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.
NextPharma operates globally with seven product development centres, seven manufacturing plants and six storage and distribution sites across Europe and North America employing over 1,200 people. Across these locations NextPharma has built-up a strong track record in the development and manufacture of cytotoxics, hormones, antibiotics, pellets, sterile, solid, semi-solid, liquid and dry dosage forms, supplying customers in North America, Europe and Japan.
NextPharma has a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.